Pathology dream deal a three-headed competition nightmare
Forget the terms of Australian Clinical Labs’ offer for Healius. What is important is what the regulator says about combining the No.2 and No.3 pathology groups.
There is nothing like a 30-page statement of issues and three red lights from the Australian Competition and Consumer Commission to pour water over a dream deal, or at the very least indicate a big battle and plenty of horse-trading in the months ahead.
The dream deal is the tie-up between two of Australia’s three biggest pathology groups, Healius and Australian Clinical Labs, to create a player with at least 50 per cent market share in the country’s most populous states.
Loading...
Anthony Macdonald is a Chanticleer columnist. He is a former Street Talk co-editor and has 10 years' experience as a business journalist and worked at PwC, auditing and advising financial services companies. Connect with Anthony on Twitter. Email Anthony at a.macdonald@afr.com
